AtriCure, Inc. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. AtriCure, Inc. is a medical device company specializing in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company operates as a single segment, selling devices globally through a direct sales force and distributors.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $136.1M | $116.3M | $259.8M | $225.1M |
| Gross Profit | $101.5M | $86.8M | $194.1M | $168.1M |
| Gross Margin | 74.5% | 74.7% | 74.7% | 74.7% |
| Net Loss | $(6.2M) | $(8.0M) | $(12.9M) | $(21.3M) |
| Operating Cash Flow (YTD) | $10.6M | $(13.6M) | $10.6M | $(13.6M) |
| Cash & Equivalents | $117.8M | $122.7M (Dec 2024) | $117.8M | $106.0M (Jun 2024) |
| Long-Term Debt | $61.9M | $61.9M | $61.9M | $61.9M |
| Unused Borrowing Capacity | $61.9M | N/A | $61.9M | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenue increased 17.1% year-over-year (16.5% on a constant currency basis). YTD revenue grew 15.4%. Growth was driven by Appendage Management (+18.9% Q2) and Pain Management (+41.1% Q2).
- Expense Increases: R&D expenses rose 43.4% in Q2 and 28.7% YTD, primarily due to a $5.0M milestone payment for acquired in-process research and development (IPR&D) and increased clinical trial costs for the LeAAPS study. SG&A expenses increased 6.5% Q2-over-Q2 due to headcount growth.
- Profitability Improvement: Net loss narrowed significantly to $6.2M in Q2 2025 from $8.0M in Q2 2024. Operating loss improved to $6.2M from $7.2M.
- Cash Flow Turnaround: Operating cash flow turned positive, providing $10.6M YTD 2025 compared to a use of $13.6M in the prior year period.
Outlook, Risks, and Unusual Items
- Product Launches: The company received FDA clearance for the AtriClip PRO-Mini and cryoICE cryoXT probe in early 2025, with launches expected in the second half of 2025.
- Clinical Trials: Enrollment for the LeAAPS trial (6,500 patients) was completed in July 2025. The BoxX-NoAF trial is expected to begin enrollment later in 2025.
- Legal Contingency: A lawsuit filed by former SentreHEART securityholders seeks up to $260M in damages regarding alleged failure to obtain PMA approval for the LARIAT System. Management intends to vigorously defend the claim; no liability has been recognized as the loss is not currently probable or estimable.
- Debt Facility: The company maintains a $125M asset-based revolving credit facility maturing in January 2027. As of June 30, 2025, $61.9M was drawn with $61.9M remaining available.
- Tax Legislation: The "One Big Beautiful Bill Act" was signed into law on July 4, 2025. The company is evaluating its impact, but it had no financial effect on the period ended June 30, 2025.
Investor Verification Checklist
- Revenue Sustainability: Verify if the 41% growth in Pain Management and 19% growth in Appendage Management is sustainable given the decline in Minimally Invasive Ablation (-33.7% Q2).
- One-Time Expenses: Confirm the impact of the $5.0M IPR&D milestone payment on future R&D guidance and whether similar milestones are expected.
- Legal Exposure: Monitor the status of the SentreHEART litigation and any potential accruals for the $260M claim.
- Cash Burn vs. Generation: Assess the transition from negative to positive operating cash flow and its ability to fund future clinical trials without additional dilution or debt.
- Debt Covenants: Review the fixed charge coverage ratio and minimum excess availability covenants under the JPMorgan/SVB credit agreement.